Overdosage can lead to acute profound water loss, volume and electrolyte depletion, dehydration, reduction of blood volume and circulatory collapse with a possibility of vascular thrombosis and embolism. Electrolyte depletion may be manifested by weakness, dizziness, mental confusion, anorexia, lethargy, vomiting and cramps. Treatment consists of replacement of fluid and electrolyte losses by careful monitoring of the urine and electrolyte output and serum electrolyte levels.
Bumetanide is a sulfamyl diuretic.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Duloxetine | The risk or severity of orthostatic hypotension and syncope can be increased when Bumetanide is combined with Duloxetine. |
| Levodopa | The risk or severity of hypotension and orthostatic hypotension can be increased when Bumetanide is combined with Levodopa. |
| Allopurinol | The risk or severity of adverse effects can be increased when Bumetanide is combined with Allopurinol. |
| Canagliflozin | The risk or severity of hypotension can be increased when Canagliflozin is combined with Bumetanide. |
| Cisplatin | The risk or severity of ototoxicity and nephrotoxicity can be increased when Bumetanide is combined with Cisplatin. |
| Dofetilide | The risk or severity of QTc prolongation, torsade de pointes, hypokalemia, hypomagnesemia, and cardiac arrest can be increased when Bumetanide is combined with Dofetilide. |
| Ivabradine | The risk or severity of Cardiac Arrhythmia can be increased when Bumetanide is combined with Ivabradine. |
| Lithium citrate | Bumetanide may decrease the excretion rate of Lithium citrate which could result in a higher serum level. |
| Lithium carbonate | Bumetanide may decrease the excretion rate of Lithium carbonate which could result in a higher serum level. |
| Lithium hydroxide | Bumetanide may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level. |
| Nicotine | The risk or severity of adverse effects can be increased when Bumetanide is combined with Nicotine. |
| Mecamylamine | The risk or severity of adverse effects can be increased when Bumetanide is combined with Mecamylamine. |
| Pentolinium | The risk or severity of adverse effects can be increased when Bumetanide is combined with Pentolinium. |
| Trimethaphan | The risk or severity of adverse effects can be increased when Bumetanide is combined with Trimethaphan. |
| Hexamethonium | The risk or severity of adverse effects can be increased when Bumetanide is combined with Hexamethonium. |
| Cyclopentamine | The risk or severity of adverse effects can be increased when Bumetanide is combined with Cyclopentamine. |
| Probenecid | The risk or severity of adverse effects can be increased when Probenecid is combined with Bumetanide. |
| Risperidone | The risk or severity of hypotension can be increased when Bumetanide is combined with Risperidone. |
| Topiramate | The risk or severity of hypokalemia can be increased when Bumetanide is combined with Topiramate. |
| Methotrexate | The therapeutic efficacy of Bumetanide can be decreased when used in combination with Methotrexate. |
| Foscarnet | Bumetanide may decrease the excretion rate of Foscarnet which could result in a higher serum level. |
| Mannitol | The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Bumetanide. |
| Tenofovir disoproxil | Bumetanide may increase the nephrotoxic activities of Tenofovir disoproxil. |
| Tenofovir alafenamide | The serum concentration of Tenofovir alafenamide can be increased when it is combined with Bumetanide. |
| Tenofovir | Bumetanide may increase the nephrotoxic activities of Tenofovir. |
| Aspartame | The excretion of Bumetanide can be decreased when combined with Aspartame. |
| Aminohippuric acid | The excretion of Bumetanide can be decreased when combined with Aminohippuric acid. |
| Lansoprazole | The excretion of Bumetanide can be decreased when combined with Lansoprazole. |
| Guanidine | The excretion of Bumetanide can be decreased when combined with Guanidine. |
| Oxytetracycline | The excretion of Bumetanide can be decreased when combined with Oxytetracycline. |
| Leucovorin | The excretion of Bumetanide can be decreased when combined with Leucovorin. |
| Esomeprazole | The excretion of Bumetanide can be decreased when combined with Esomeprazole. |
| Succinic acid | The excretion of Succinic acid can be decreased when combined with Bumetanide. |
| Citrulline | The excretion of Citrulline can be decreased when combined with Bumetanide. |
| Cefdinir | The excretion of Cefdinir can be decreased when combined with Bumetanide. |
| Fluorescein | The excretion of Fluorescein can be decreased when combined with Bumetanide. |
| Hydrocortisone | The excretion of Hydrocortisone can be decreased when combined with Bumetanide. |
| Dinoprostone | The excretion of Dinoprostone can be decreased when combined with Bumetanide. |
| Famotidine | The excretion of Famotidine can be decreased when combined with Bumetanide. |
| Fexofenadine | The excretion of Fexofenadine can be decreased when combined with Bumetanide. |
| Tazobactam | The excretion of Tazobactam can be decreased when combined with Bumetanide. |
| Cyclic adenosine monophosphate | The excretion of Cyclic adenosine monophosphate can be decreased when combined with Bumetanide. |
| Cholic Acid | The excretion of Cholic Acid can be decreased when combined with Bumetanide. |
| Glutaric Acid | The excretion of Glutaric Acid can be decreased when combined with Bumetanide. |
| Oxalic Acid | The excretion of Oxalic Acid can be decreased when combined with Bumetanide. |
| Taurocholic acid | The excretion of Taurocholic acid can be decreased when combined with Bumetanide. |
| Ellagic acid | The excretion of Ellagic acid can be decreased when combined with Bumetanide. |
| Avibactam | The excretion of Avibactam can be decreased when combined with Bumetanide. |
| Silibinin | The excretion of Silibinin can be decreased when combined with Bumetanide. |
| Relebactam | The excretion of Relebactam can be decreased when combined with Bumetanide. |
| Novobiocin | The excretion of Bumetanide can be decreased when combined with Novobiocin. |
| Melatonin | The excretion of Bumetanide can be decreased when combined with Melatonin. |
| Liotrix | The excretion of Bumetanide can be decreased when combined with Liotrix. |
| Cilastatin | The excretion of Bumetanide can be decreased when combined with Cilastatin. |
| trans-2-hydroxycinnamic acid | The excretion of Bumetanide can be decreased when combined with trans-2-hydroxycinnamic acid. |
| Benzoic acid | The excretion of Bumetanide can be decreased when combined with Benzoic acid. |
| Caprylic acid | The excretion of Bumetanide can be decreased when combined with Caprylic acid. |
| Ataluren | The excretion of Bumetanide can be decreased when combined with Ataluren. |
| Teriflunomide | The excretion of Bumetanide can be decreased when combined with Teriflunomide. |
| Dabrafenib | The excretion of Bumetanide can be decreased when combined with Dabrafenib. |
| Dolutegravir | The excretion of Bumetanide can be decreased when combined with Dolutegravir. |
| Lenvatinib | The excretion of Bumetanide can be decreased when combined with Lenvatinib. |
| Cabotegravir | The excretion of Bumetanide can be decreased when combined with Cabotegravir. |
| Pradigastat | The excretion of Bumetanide can be decreased when combined with Pradigastat. |
| Enasidenib | The excretion of Bumetanide can be decreased when combined with Enasidenib. |
| Enalapril | The excretion of Bumetanide can be decreased when combined with Enalapril. |
| Quinapril | The excretion of Quinapril can be decreased when combined with Bumetanide. |
| Captopril | The excretion of Captopril can be decreased when combined with Bumetanide. |
| Cefotiam | The excretion of Bumetanide can be decreased when combined with Cefotiam. |
| Cefalotin | The excretion of Bumetanide can be decreased when combined with Cefalotin. |
| Cefotaxime | The excretion of Bumetanide can be decreased when combined with Cefotaxime. |
| Cephalexin | The excretion of Bumetanide can be decreased when combined with Cephalexin. |
| Valaciclovir | The excretion of Valaciclovir can be decreased when combined with Bumetanide. |
| Acyclovir | The excretion of Bumetanide can be decreased when combined with Acyclovir. |
| Cefaclor | The excretion of Bumetanide can be decreased when combined with Cefaclor. |
| Pantoprazole | The excretion of Bumetanide can be decreased when combined with Pantoprazole. |
| Cefadroxil | The excretion of Bumetanide can be decreased when combined with Cefadroxil. |
| Ceftriaxone | The excretion of Bumetanide can be decreased when combined with Ceftriaxone. |
| Ceftibuten | The excretion of Ceftibuten can be decreased when combined with Bumetanide. |
| Cefamandole | The excretion of Bumetanide can be decreased when combined with Cefamandole. |
| Cefazolin | The excretion of Cefazolin can be decreased when combined with Bumetanide. |
| Cefoperazone | The excretion of Bumetanide can be decreased when combined with Cefoperazone. |
| Ceftizoxime | The excretion of Ceftizoxime can be decreased when combined with Bumetanide. |
| Cefacetrile | The excretion of Cefacetrile can be decreased when combined with Bumetanide. |
| Cefaloridine | The excretion of Cefaloridine can be decreased when combined with Bumetanide. |
| Dronedarone | The excretion of Bumetanide can be decreased when combined with Dronedarone. |
| Favipiravir | The excretion of Bumetanide can be decreased when combined with Favipiravir. |
| Tafamidis | The excretion of Bumetanide can be decreased when combined with Tafamidis. |
| Dexamethasone acetate | The excretion of Dexamethasone acetate can be decreased when combined with Bumetanide. |
| Acamprosate | The excretion of Acamprosate can be decreased when combined with Bumetanide. |
| Aripiprazole | Aripiprazole may increase the hypotensive activities of Bumetanide. |
| Aripiprazole lauroxil | Aripiprazole lauroxil may increase the hypotensive activities of Bumetanide. |
| Nicorandil | Nicorandil may increase the hypotensive activities of Bumetanide. |
| Ouabain | The risk or severity of adverse effects can be increased when Bumetanide is combined with Ouabain. |
| Acetyldigitoxin | The risk or severity of adverse effects can be increased when Bumetanide is combined with Acetyldigitoxin. |
| Deslanoside | The risk or severity of adverse effects can be increased when Bumetanide is combined with Deslanoside. |
| Digitoxin | The risk or severity of adverse effects can be increased when Bumetanide is combined with Digitoxin. |
| Oleandrin | The risk or severity of adverse effects can be increased when Bumetanide is combined with Oleandrin. |
| Cymarin | The risk or severity of adverse effects can be increased when Bumetanide is combined with Cymarin. |
| Proscillaridin | The risk or severity of adverse effects can be increased when Bumetanide is combined with Proscillaridin. |